1. Home
  2. SER vs NSAI Comparison

SER vs NSAI Comparison

Compare SER & NSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$1.70

Market Cap

56.4M

Sector

Health Care

ML Signal

HOLD

NSAI

NorthStrive Acquisition Corp I. Class A Ordinary Shares

N/A

Current Price

$9.92

Market Cap

47.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SER
NSAI
Founded
2017
2026
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.4M
47.7M
IPO Year
2024
2026

Fundamental Metrics

Financial Performance
Metric
SER
NSAI
Price
$1.70
$9.92
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $9.50
N/A
AVG Volume (30 Days)
★ 28.7K
7.4K
Earning Date
11-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $130,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 132.14
N/A
52 Week Low
$1.22
$9.86
52 Week High
$5.29
$9.94

Technical Indicators

Market Signals
Indicator
SER
NSAI
Relative Strength Index (RSI) 35.23 56.82
Support Level $1.73 N/A
Resistance Level $1.86 $9.94
Average True Range (ATR) 0.11 0.01
MACD -0.02 0.00
Stochastic Oscillator 15.38 46.31

Price Performance

Historical Comparison
SER
NSAI

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

About NSAI NorthStrive Acquisition Corp I. Class A Ordinary Shares

NorthStrive Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Share on Social Networks: